TY - JOUR T1 - Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor JF - medRxiv DO - 10.1101/2020.04.06.20055475 SP - 2020.04.06.20055475 AU - Xiangyu Chen AU - Ren Li AU - Zhiwei Pan AU - Chunfang Qian AU - Yang Yang AU - Renrong You AU - Jing Zhao AU - Pinghuang Liu AU - Leiqiong Gao AU - Zhirong Li AU - Qizhao Huang AU - Lifan Xu AU - Jianfang Tang AU - Qin Tian AU - Wei Yao AU - Li Hu AU - Xiaofeng Yan AU - Xinyuan Zhou AU - Yuzhang Wu AU - Kai Deng AU - Zheng Zhang AU - Zhaohui Qian AU - Yaokai Chen AU - Lilin Ye Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055475.abstract N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Fund for Distinguished Young Scholars (No. 31825011 to L.Y.) and the Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control (No. cstc2020jscx-2 to L.Y.; No. cstc2020jscx-fyzx0074 to Y.C.; cstc2020jscx-fyzx0135 to Y.C.).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the manuscript are of availability. ER -